GBS vs. GA: Treating Both Acute & Chronic Diseases with C1q Inhibition
Time: 1:30 pm
day: Conference Day One
Details:
- Discussing the efficacy of ANX005 in treating Guillain-Barre Syndrome
- Optimizing dosage for acute and chronic indications
- Summarizing the differences in the challenges of complement inhibition in acute and chronic indications
